Quantitative model for efficient temporal targeting of tumor cells and neovasculature

Computational and Mathematical Methods in Medicine

Volumn 2011, Issue , 2011, Pages

  Kohandel, M ^a,b   Haselwandter, C A ^c,d   Kardar, M ^c   Sengupta, S ^e   Sivaloganathan, S ^a,b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b FIELDS INSTITUTE   (Canada)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d California Institute of Technology   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOTECHNOLOGY;

ANTIANGIOGENIC AGENT; CHEMOTHERAPEUTIC AGENTS; MALIGNANT TUMORS; NANOSCALE DELIVERY SYSTEMS; NEOVASCULATURE; NUMERICAL RESULTS; QUANTITATIVE MODELING; TUMOR TISSUES;

TUMORS;

ANTINEOPLASTIC AGENT; COMBRETASTATIN; COMBRETASTATIN PLUS DOXORUBICIN; DOXORUBICIN; LIPOSOME; NANOCELL; NANOCOATING; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; BIBENZYL DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG RELEASE; DRUG TARGETING; LEWIS CARCINOMA; MALE; MATHEMATICAL MODEL; MELANOMA; MELANOMA B16; MOUSE; NANOPHARMACEUTICS; NONHUMAN; SENSITIVITY ANALYSIS; SIMULATION; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; ALGORITHM; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; COMPUTER SIMULATION; EXPERIMENTAL MELANOMA; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TIME; TREATMENT OUTCOME; VASCULARIZATION;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIBENZYLS; BIOLOGICAL AVAILABILITY; CARCINOMA, LEWIS LUNG; COMPUTER SIMULATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MODELS, BIOLOGICAL; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955111198     PISSN: 1748670X     EISSN: 17486718     Source Type: Journal    
DOI: 10.1155/2011/790721     Document Type: Article

References (25)

1. Jain R. K., Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nature Medicine 2001 7 9 987 989 (Pubitemid 32937367)
2. Jain R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005 307 5706 58 62 (Pubitemid 40093472)
3. Murata R., Nishimura Y., Hiraoka M., An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma International Journal of Radiation Oncology Biology Physics 1997 37 5 1107 1113 (Pubitemid 27230036)
4. Bello L., Carrabba G., Giussani C., Lucini V., Cerutti F., Scaglione F., Landr J., Pluderi M., Tomei G., Villani R., Carroll R. S., Black P. MC. L., Bikfalvi A., Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo Cancer Research 2001 61 20 7501 7506 (Pubitemid 32995040)
5. Ma J., Pulfer S., Li S., Chu J., Reed K., Gallo J. M., Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470 Cancer Research 2001 61 14 5491 5498 (Pubitemid 32694932)
6. Rofstad E. K., Henriksen K., Galappathi K., Mathiesen B., Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts Cancer Research 2003 63 14 4055 4061 (Pubitemid 36917927)
7. Zips D., Krause M., Hessel F., Westphal J., Brchner K., Eicheler W., Drfler A., Grenman R., Petersen C., Haberey M., Baumann M., Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation Anticancer Research 2003 23 5 3869 3876 (Pubitemid 37474336)
8. Fenton B. M., Paoni S. F., Ding I., Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors Radiotherapy and Oncology 2004 72 2 221 230 (Pubitemid 39024597)
9. Ma J., Waxman D. J., Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Molecular Cancer Therapeutics 2008 7 12 3670 3684
10. Tong R. T., Boucher Y., Kozin S. V., Winkler F., Hicklin D. J., Jain R. K., Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Research 2004 64 11 3731 3736 (Pubitemid 38697278)
11. Willett C. G., Boucher Y., Di Tomaso E., Duda D. G., Munn L. L., Tong R. T., Chung D. C., Sahani D. V., Kalva S. P., Kozin S. V., Mino M., Cohen K. S., Scadden D. T., Hartford A. C., Fischman A. J., Clark J. W., Ryan D. P., Zhu A. X., Blaszkowsky L. S., Chen H. X., Shellito P. C., Lauwers G. Y., Jain R. K., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Medicine 2004 10 2 145 147 (Pubitemid 38524883)
12. Winkler F., Kozin S. V., Tong R. T., Chae S. S., Booth M. F., Garkavtsev I., Xu L., Hicklin D. J., Fukumura D., Di Tomaso E., Munn L. L., Jain R. K., Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 2004 6 6 553 563 (Pubitemid 40017699)
13. Kashiwagi S., Tsukada K., Xu L., Miyazaki J., Kozin S. V., Tyrrell J. A., Sessa W. C., Gerweck L. E., Jain R. K., Fukumura D., Perivascular nitric oxide gradients normalize tumor vasculature Nature Medicine 2008 14 3 255 257 (Pubitemid 351347918)
14. Franco M., Man S., Chen L., Emmenegger U., Shaked Y., Cheung A. M., Brown A. S., Hicklin D. J., Foster F. S., Kerbel R. S., Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia Cancer Research 2006 66 7 3639 3648
15. Hormigo A., Gutin P. H., Rafii S., Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers Cancer Cell 2007 11 1 6 8 (Pubitemid 46054523)
16. Batchelor T. T., Sorensen A. G., di Tomaso E., Zhang W. T., Duda D., Cohen K. S., Kozak K. R., Cahill D. P., Chen P. J., Zhu M., Ancukiewicz M., Mrugala M. M., Plotkin S., Drappatz J., Louis D. N., Ivy P., Scadden D., Benner T., Loeffler J. S., Wen P. Y., Jain R. K., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 2007 11 1 83 95 (Pubitemid 46075199)
17. Pugh C. W., Ratcliffe P. J., Regulation of angiogenesis by hypoxia: role of the HIF system Nature Medicine 2003 9 6 677 684 (Pubitemid 36749216)
18. Bristow R. G., Hill R. P., Hypoxia and metabolism: hypoxia, DNA repair and genetic instability Nature Reviews Cancer 2008 8 3 180 192 (Pubitemid 351301853)
19. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R., Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 2005 436 7050 568 572 (Pubitemid 41112931)
20. Yuan F., Leunig M., Huang S. K., Berk D. A., Papahadjopoulos D., Jain R. K., Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Research 1994 54 13 3352 3356 (Pubitemid 24225946)
21. Sengupta S., Sasisekharan R., Exploiting nanotechnology to target cancer British Journal of Cancer 2007 96 9 1315 1319 (Pubitemid 46685778)
22. Kohandel M., Kardar M., Milosevic M., Sivaloganathan S., Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies Physics in Medicine and Biology 2007 52 13 3665 3677 (Pubitemid 46908587)
23. Perrault S. D., Walkey C., Jennings T., Fischer H. C., Chan W. C. W., Mediating tumor targeting efficiency of nanoparticles through design Nano Letters 2009 9 5 1909 1915
24. Jain R. K., Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer Nature Reviews Cancer 2008 8 4 309 316 (Pubitemid 351430862)
25. de Pillis L. G., Radunskaya A. E., Wiseman C. L., A validated mathematical model of cell-mediated immune response to tumor growth Cancer Research 2005 65 17 7950 7958 (Pubitemid 41297274)